GenVivo
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
475 Huntington Dr, San Marino, Californi...Phone Number
(626) 441-6695Website
www.genvivoinc.comRevenue
$6.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About GenVivo
GenVivo is a Biotechnology company in San Marino, California, that develops innovative gene therapies to treat cancer and prolong patient survival while improving quality of life.Explore more
GenVivo Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GenVivo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if GenVivo had a recent Job posting/layoffs
Earning: See what the market has to say on GenVivo recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at GenVivo
Product Launch: Get notified when GenVivo launches new products
Check out if GenVivo is spiking on competitors!
GenVivo, which may be a good buyer, showed buying intent in Masked Content Topic
Check if GenVivo has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once GenVivo has new funding data
Recommended Actions
Find VP level buyers at GenVivo
Find 3 more new buyers
Compare Similar Companies to GenVivo
Compare insights from companies similar to GenVivo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
GenVivo
$6.7M
11-50
Private
-
2001
Carol StuckleyInterim Chief Financial Officer & Chief Financial Officer
Company Profile Activity
Activity Insights
GenVivo is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GenVivo is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GenVivo.
GenVivo Tech Stack
A closer look at the technologies used by GenVivo
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Open Position
Open Position
GenVivo News & Media
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
SAN MARINO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the entire repertoire of their own tumor antigens, today announces the appointment of Dr. Noriyuki “Nori” Kasahara as Chief Scientific Officer (CSO).GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
Non-integrating retrovectors represent a novel and attractive tool that has potential advantages for gene delivery and vaccinology.GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
SAN MARINO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform to combat cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting updated Phase 1 clinical data on GEN2 and preclinical data on GEN-1013 at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting, May 13th – 17th, in New Orleans, LA.GenVivo Highlights GEN-1013: A Novel Delivery of an IL-12 Immunotherapy at the 2025 American Association for Cancer Research (AACR) Annual Meeting
PASADENA, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that fights cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting compelling preclinical data on GEN-1013, an Interleukin-12 (IL-12) immunotherapy, at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25th – 30th, in Chicago, IL.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GenVivo
Sign Up For FreeTo access detailed company insights
GenVivo is a Biotechnology company in San Marino, California, that develops innovative gene therapies to treat cancer and prolong patient survival while improving quality of life.... Read More
